文献速递肝病

线粒体二羧酸载体通过抑制白色脂肪细胞脂解防止肝脏脂毒性

The mitochondrial dicarboxylate carrier prevents hepatic lipotoxicity by inhibiting white adipocyte lipolysis.
PubMed 文献 · J Hepatol · 2021-03-18

该研究通过脂肪细胞特异性敲除或过表达mDIC的小鼠模型,发现mDIC将线粒体琥珀酸转运至胞质,激活SUCNR1抑制脂解;敲除加剧高脂饮食诱导的肝脏脂毒性和胰岛素抵抗,过表达则保护肝脏并改善糖耐量,人类数据提示mDIC与胰岛素敏感性正相关、与肝内甘油三酯负相关。

要点

  • mDIC通过琥珀酸-SUCNR1轴抑制脂肪细胞脂解
  • 脂肪细胞mDIC缺失加剧高脂饮食诱导的肝脏脂毒性和胰岛素抵抗
  • 脂肪细胞mDIC过表达可预防肝脏脂毒性并改善糖代谢

核心结论

  • mDIC在调控脂肪细胞脂解和防止高脂饮食诱导的肝脏脂毒性中起关键作用。

研究设计与样本

  • 研究构建了可多西环素诱导的脂肪细胞特异性mDIC敲除(mDICiKO)和过表达(mDICiOE)小鼠模型。
  • 体外使用分化的白色脂肪细胞进行机制研究。
  • 此外分析了人类白色脂肪组织SLC25A10 mRNA水平与代谢指标的相关性。

主要发现

  • 在体外分化的白色脂肪细胞中,mDIC负责将琥珀酸从线粒体基质转运至胞质,琥珀酸作用于SUCNR1受体,抑制cAMP-磷酸化激素敏感性脂肪酶(pHSL)通路从而抑制脂解。
  • mDICiKO小鼠表现出脂肪细胞脂解增强,并促进高脂饮食诱导的脂肪细胞功能障碍、肝脏脂毒性和全身胰岛素抵抗。
  • mDICiOE小鼠在体内和离体均显示脂肪细胞脂解受抑制,高脂饮食喂养后受到显著保护免于肝脏脂毒性。
  • mDICiOE小鼠对高脂饮食诱导的体重增加和脂肪组织扩张有抵抗,同时糖耐量和胰岛素敏感性改善。
  • 人类白色脂肪组织SLC25A10 mRNA水平与胰岛素敏感性正相关,与肝内甘油三酯水平负相关。

临床怎么用

  • mDIC-琥珀酸轴可能成为治疗脂肪肝疾病的靶点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: We have previously reported that the mitochondrial dicarboxylate carrier (mDIC [SLC25A10]) is predominantly expressed in the white adipose tissue (WAT) and subject to regulation by metabolic cues. However, the specific physiological functions of mDIC and the reasons for its abundant presence in adipocytes are poorly understood. METHODS: To systemically investigate the impact of mDIC function in adipocytes in vivo, we generated loss- and gain-of-function mouse models, selectively eliminating or overexpressing mDIC in mature adipocytes, respectively. RESULTS: In in vitro differentiated white adipocytes, mDIC is responsible for succinate transport from the mitochondrial matrix to the cytosol, from where succinate can act on the succinate receptor SUCNR1 and inhibit lipolysis by dampening the cAMP- phosphorylated hormone-sensitive lipase (pHSL) pathway. We eliminated mDIC expression in adipocytes in a doxycycline (dox)-inducible manner (mDICiKO) and demonstrated that such a deletion results in enhanced adipocyte lipolysis and promotes high-fat diet (HFD)-induced adipocyte dysfunction, liver lipotoxicity, and systemic insulin resistance. Conversely, in a mouse model with dox-inducible, adipocyte-specific overexpression of mDIC (mDICiOE), we observed suppression of adipocyte lipolysis both in vivo and ex vivo. mDICiOE mice are potently protected from liver lipotoxicity upon HFD feeding. Furthermore, they show resistance to HFD-induced weight gain and adipose tissue expansion with concomitant improvements in glucose tolerance and insulin sensitivity. Beyond our data in rodents, we found that human WAT SLC25A10 mRNA levels are positively correlated with insulin sensitivity and negatively correlated with intrahepatic triglyceride levels, suggesting a critical role of mDIC in regulating overall metabolic homeostasis in humans as well. CONCLUSIONS: In summary, we highlight that mDIC plays an essential role in governing adipocyte lipolysis and preventing liver lipotoxicity in response to a HFD. LAY SUMMARY: Dysfunctional fat tissue plays an important role in the development of fatty liver disease and liver injury. Our present study identifies a mitochondrial transporter, mDIC, which tightly controls the release of free fatty acids from adipocytes to the liver through the export of succinate from mitochondria. We believe this mDIC-succinate axis could be targeted for the treatment of fatty liver disease.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. An YA, Chen S, Deng Y, et al. The mitochondrial dicarboxylate carrier prevents hepatic lipotoxicity by inhibiting white adipocyte lipolysis. J Hepatol. 2021. PMID: 33746082. doi:10.1016/j.jhep.2021.03.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。